ADCT vs JNJ · rev $40.1M vs P/E 17, rev $49.37B
ADC Therapeutics SA (ADCT) versus Johnson & Johnson (JNJ) — a side-by-side from cached financials, not a winner call.
ADC Therapeutics SA (ADCT) is a biotechnology company listed on NYSE.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
Latest reported ADCT revenue for 2026-06-30 was $40.1M. Net income was -$49.5M. Revenue was up 92.3% from 2026-03-31 to 2026-06-30. ADCT currently screens at market cap $141.2M.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
ADCT currently screens at market cap $141.2M. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Not investment advice. Open the ADCT and JNJ stock pages for the full models.
Not investment advice.